Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Calsequestrin 2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5102970
Description
Antibody detects endogenous levels of total CASQ2.
Calsequestrin (CASQ) is a Ca2+-binding protein present primarily in junctional sarcoplasmic reticulum of skeletal and cardiac muscle; the cardiac form (CASQ2) is encoded by a separate gene. The primary role of CASQ2 is buffering of the sarcoplasmic reticulum Ca2+ ions, but another role for CASQ2 has emerged recently: CASQ2 regulates the open probability of ryanodine receptor 2 (RyR2). Mutations in CASQ2 cause stress-induced polymorphic ventricular tachycardia, also referred to as catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2), a disease characterized by bidirectional ventricular tachycardia that may lead to cardiac arrest.
Specifications
Calsequestrin 2 | |
Polyclonal | |
Unconjugated | |
Casq2 | |
AA033488; AW146219; calsequestrin; calsequestrin 2; calsequestrin 2 (cardiac muscle); calsequestrin 2, fast-twitch, cardiac muscle; calsequestrin, cardiac muscle isoform; Calsequestrin-2; cardCSQ; cardiac calsequestrin; CASQ2; cCSQ; Csq2; ESTM52; LOW QUALITY PROTEIN: calsequestrin-2; PDIB2; SR calcium binding protein | |
Rabbit | |
Affinity Chromatography | |
RUO | |
12373, 29209, 845 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
O09161, O14958, P51868 | |
Casq2 | |
A synthesized peptide derived from human CASQ2(Accession O14958), corresponding to amino acid residues A272-F322. | |
100 μL | |
Primary | |
Human, Mouse, Rat, Monkey | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction